Videos

Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results from Dr Krish Patel.

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing.

ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.

Current NCCN guidelines for early-stage NSCLC recommend testing for key biomarkers to guide decisions regarding adjuvant targeted therapy or immunotherapy.

Matthew Matasar, MD, discusses real-world data on treatment options for diffuse large B-cell lymphoma.

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated DLBCL patients, without rituximab.

Explore the latest trials on eltrombopag and elritercept, promising new treatments for low-risk MDS and CMML with TET2 mutations.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, enhancing treatment strategies.

A recent study highlights the benefits of early luspatercept treatment for patients with hemoglobin above 8, improving outcomes before transfusion dependency.

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and real-world evidence supporting its use.

A recent analysis reveals that low-risk MDS patients with earlier-stage profiles respond better to luspatercept, suggesting earlier treatment benefits.

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

A recent study explores inflammatory profiles in low-risk MDS, revealing distinct patient categories and implications for treatment strategies.

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment strategies.

Explore the clinical considerations for choosing between ESAs and luspatercept in treating low-risk MDS, focusing on efficacy and patient convenience.

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality of life and treatment options.

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality of life.

Discover how a metal statin offers a promising backup treatment for MDS patients, enhancing transfusion outcomes while requiring careful monitoring.

Luspatercept emerges as a preferred treatment for low-risk MDS, enhancing hemoglobin levels and quality of life, even in diverse patient subgroups.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications like iron overload.

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies.

Dr Robert Orlowski highlights strategies to prevent infections in patients with multiple myeloma treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.

Explore the significance of MRD negativity in cancer prognosis and its implications for treatment strategies in community-based practices.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

Martin F. Dietrich, MD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.